Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of a safety and efficacy analysis

被引：0
|
作者：
Arkenau, HT
Schmoll, H
Kubicka, S
Kretzschmar, A
Freier, W
Seufferlein, T
Graeven, U
Grothey, A
Hinke, A
Porschen, R
机构：
[1] Clin Bremen E, Clin Internal Med, Bremen, Germany
[2] Univ Halle Wittenberg, Halle Saale, Germany
[3] Hannover Med Sch, D-3000 Hannover, Germany
[4] Charite, Berlin, Germany
[5] Private Oncol Clin, Hildesheim, Germany
[6] Univ Ulm, Med Clin, Ulm, Germany
[7] Hosp Maria Hilf, Monchengladbach, Germany
[8] Mayo Clin, Rochester, MN USA
[9] Res Inst WISP Langenfeld, Res Inst WISP, Langenfeld, Germany
[10] Clin Bremen E 10, Bremen, Germany
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：283 / 283
页数：1
相关论文
共 50 条
  • [1] Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysis
    Arkenau, H.
    Kubicka, S.
    Greil, R.
    Schmoll, H.
    Seufferlein, T.
    Greaven, U.
    Grothey, A.
    Kretschmar, A.
    Hinke, A.
    Porschen, R.
    EJC SUPPLEMENTS, 2005, 3 (02): : 168 - 168
  • [2] Infusiorial 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis.
    Arkenau, HT
    Schmoll, H
    Kubicka, S
    Kretzschmar, A
    Freier, W
    Seufferlein, T
    Graeven, U
    Grothey, A
    Hinke, A
    Porschen, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 247S - 247S
  • [3] Final results of a randomized comparison of infusional 5-fluorouracil/leucovorin plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) in metastatic colorectal carcinoma (MCRC)
    Porschen, Rainer
    Kubicka, S.
    Grothey, A.
    Grateven, U.
    Kretzschmar, A.
    Greil, R.
    Freier, W.
    Seufferlein, T.
    Arkenau, Ht
    Hinke, A.
    Schmoll, Hj
    Schmiegel, W.
    GASTROENTEROLOGY, 2006, 130 (04) : A582 - A582
  • [4] Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): Results of an interim safety analysis.
    Arkenau, HT
    Schmoll, H
    Kubicka, S
    Seufferlein, T
    Reichardt, P
    Freier, W
    Graeven, U
    Grothey, A
    Porschen, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 256S - 256S
  • [5] Phase III trial of infusional 5-fluorouracil/folinic acid plus oxalipiatin (FUFOX) versus capecitabine plus oxalipiatin (CAPOX) as first line treatment of advanced colorectal carcinoma (ACRC): results of an interim efficacy and safety analysis
    Arkenau, Hendrik T.
    Kubicka, S.
    Grall, R.
    Seufferlein, T.
    Freier, W.
    Graeven, U.
    Grothey, A.
    Hinke, A.
    Schmoll, H.
    Porschen, R.
    ANNALS OF ONCOLOGY, 2004, 15 : 72 - 72
  • [6] Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
    Ducreux, Michel
    Bennouna, Jaafar
    Hebbar, Mohamed
    Ychou, Marc
    Lledo, Gerard
    Conroy, Thierry
    Adenis, Antoine
    Faroux, Roger
    Rebischung, Christine
    Bergougnoux, Loic
    Kockler, Leila
    Douillard, Jean-Yves
    INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (03) : 682 - 690
  • [7] Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer
    von Weikersthal, Ludwig Fischer
    Schalhorn, Andreas
    Stauch, Martina
    Quietzsch, Detlef
    Maubach, Peter A.
    Lambertz, Helmut
    Oruzio, Daniel
    Schlag, Rudolf
    Weigang-Koehler, Karin
    Vehling-Kaiser, Ute
    Schulze, Manfred
    Truckenbrodt, Juergen
    Goebeler, Mariele
    Mittermueller, Johann
    Bosse, Daniel
    Szukics, Borika
    Grundeis, Marc
    Zwingers, Thomas
    Giessen, Clemens
    Heinemann, Volker
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (02) : 206 - 214
  • [8] PHARMACOECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS 5-FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE FIRST LINE TREATMENT OF METASTASIS COLORECTAL CANCER IN TAIWAN
    Chen, H. H.
    Chang, C. S.
    Chen, L. T.
    Chen, W. T.
    Hsu, T. C.
    Wang, J. Y.
    Wen, C. Y.
    VALUE IN HEALTH, 2009, 12 (07) : A278 - A278
  • [9] An oxaliplatin plus 5-fluorouracil bolus plus folinic acid (BFOL) regimen as first-line treatment in metastatic colorectal cancer patients
    La Verde, Nicla
    Garassino, Marina
    Bareggi, Claudia
    Sburlati, Paola
    Borgonovo, Karen
    Dimaiuta, Mariastella
    Mantica, Cristina
    Perrone, Silvia
    Torri, Valter
    Farina, Gabriella
    TUMORI, 2007, 93 (06) : 557 - 561
  • [10] Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer
    Lordick, F
    Lorenzen, S
    Stollfuss, J
    Vehling-Kaiser, U
    Kullmann, F
    Hentrich, M
    Zumschlinge, R
    Dietzfelbinger, H
    Thoedtmann, J
    Hennig, M
    Seroneit, T
    Bredenkamp, R
    Duyster, J
    Peschel, C
    BRITISH JOURNAL OF CANCER, 2005, 93 (02) : 190 - 194
12345